The impact of ivacaftor on sinonasal pathology in S1251N-mediated cystic fibrosis patients.
<h4>Importance</h4>Sinonasal symptoms in patients suffering from cystic fibrosis can negatively influence the quality of life and sinuses can be a niche for pathogens causing infection and inflammation leading to a decrease of lung function. Ivacaftor, a potentiator of the Cystic Fibrosi...
Main Authors: | Romee Gostelie, Inge Stegeman, Gitte Berkers, Joost Bittermann, Ivonne Ligtenberg-van der Drift, Peter-Jan van Kipshagen, Karin de Winter-de Groot, Lucienne Speleman |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0235638 |
Similar Items
-
Individual and Group Response of Treatment with Ivacaftor on Airway and Gut Microbiota in People with CF and a S1251N Mutation
by: Maartje I. Kristensen, et al.
Published: (2021-04-01) -
Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations
by: Joseph M. Pilewski, et al.
Published: (2020-09-01) -
Pancreatitis in A Patient with Cystic Fibrosis Taking Ivacaftor
by: Argyri Petrocheilou, et al.
Published: (2020-01-01) -
An Outbursting Protostar: The Environment of L1251 VLA 6
by: Ava Nederlander, et al.
Published: (2024-01-01) -
Lumacaftor/ivacaftor changes the lung microbiome and metabolome in cystic fibrosis patients
by: Anne H. Neerincx, et al.
Published: (2021-04-01)